United Therapeutics Corporation
United Therapeutics Corporation (UTHR) is a US-based biotechnology company focused on therapies for pulmonary arterial hypertension (PAH) and related rare diseases. It markets prostacyclin-class and inhaled therapies across intravenous, oral and inhalation routes, generating recurring revenues from long-term treatments. The company also invests heavily in organ manufacturing and regenerative medicine — including xenotransplantation and bioengineered-lung research — targeting chronic transplant shortages. Its financial profile blends cash-generating marketed drugs with high-risk, high-reward R&D programmes. Key considerations for investors include clinical trial outcomes, regulatory approvals, pricing and reimbursement dynamics, and patent lifecycles. Market capitalisation is around $19.11 billion, reflecting both existing product cash flows and longer-term innovation hopes. This summary aims to inform and educate; it is not personalised investment advice. Values can fall as well as rise, and prospective investors should consider their own risk tolerance and seek independent advice where appropriate.
Why It's Moving
Analysts Boost UTHR Targets Amid Biotech Momentum, Signaling Strong Growth Potential.
- Cantor Fitzgerald hiked its target to $625 on March 12, highlighting robust drug performance and expansion prospects.
- UBS lifted to a lofty $705 on March 5, citing accelerated revenue from key pulmonary treatments.
- Wells Fargo adjusted to $486 on March 23, underscoring steady demand despite broader market pressures.
Analysts Boost UTHR Targets Amid Biotech Momentum, Signaling Strong Growth Potential.
- Cantor Fitzgerald hiked its target to $625 on March 12, highlighting robust drug performance and expansion prospects.
- UBS lifted to a lofty $705 on March 5, citing accelerated revenue from key pulmonary treatments.
- Wells Fargo adjusted to $486 on March 23, underscoring steady demand despite broader market pressures.
When is the next earnings date for United Therapeutics Corporation (UTHR)?
United Therapeutics (UTHR) is estimated to report its next earnings between April 29 and May 6, 2026, as the company has not yet announced an official date, with projections based on historical patterns. This release will cover results for the first quarter of 2026 (Q1 2026). Investors should monitor official company announcements for confirmation, following the most recent report on February 25, 2026, for Q4 2025.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying United Therapeutics' stock despite its current price being higher than the target.
Financial Health
United Therapeutics is performing well with strong profit margins and healthy cash flow.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring UTHR
Domestic Pharma Tariffs: What's Next for Investors
The U.S. government has imposed a 100% tariff on pharmaceuticals from companies lacking domestic manufacturing, aiming to reshore production. This policy creates a significant advantage for U.S.-based pharmaceutical companies and their supply chains, which are poised for growth as reliance on imports decreases.
Published: September 26, 2025
Explore BasketNew Opportunities in Endometriosis Treatment
This carefully selected group of biopharmaceutical stocks represents companies that could benefit from Organon's recent discontinuation of its endometriosis drug. Our analysts have identified these firms as potential leaders in addressing the significant unmet needs in women's health.
Published: July 3, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pulmonary therapies
Established PAH medicines provide recurring revenue and clinical data; watch trial readouts and competition, though outcomes can vary.
Organ manufacturing
Work on xenotransplantation and bioengineered lungs targets a major unmet need, but timelines and regulatory paths are long and uncertain.
Commercial footing
A largely US-driven revenue base with growing international reach; pricing, patents and reimbursement will shape future returns.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
